Indeed, Caracciolo et al.[148] highlighted the potential of using PARP inhibition in MM, in particular in the case of bortezomib resistance, pointing to a new role of MYC in driving PARP-1 mediated repair. The gene discussed is PARP1; the disease is Miyoshi myopathy.